Avant Diagnostics, a medical technology company, continues its objective of mapping out the entire DNA sequence of a human genome. This development would benefit the entire human population as scientists would be able to treat, prevent, and cure disease. Genome is the genetic material of an organism that consists of DNA and therefore acts as a textbook of how the human body works. Scientists would be able to identify a person’s propensity of disease through testing which would promote early treatment and hopefully a cure.
Leading this innovative company as its president and CEO stands Gregg Lynn. After receiving his Master’s degree in Business Administration, summa cum laude, from Pace University-New York City in 1992, he held various Senior Financial Management positions at Fortune 500 companies and also acted as Senior Financial Analyst at Shearson Lehman. During 2001-2007, Lynn held the positions of Chief Executive Officer and Chief Financial Officer at various companies including Red Rock Advisors, LLC. In 2008, he became the president and managing member of Issuers Capital Advisors, LLC. Then in 2012, Lynn became the Chief Operating Officer and Chief Financial Officer of Avant Diagnostics which led to his current position. His successful resume speaks for itself of his qualifications and promising future with Avant Diagnostics.
For the science and technology aspect of the company there is the Scientific Advisory Board where Robert Bowser, PhD sits. The Neurology and Neurobiology professor studies the causes and potential treatments for ALS, Parkinson’s disease, Alzheimer’s disease, and more at the Barrow Neurological Institute. He’s received various federal grants and U.S. patents while lecturing extensively all over the world. Holding a graduate degree from Yale, Bowser boasts a 17-year faculty position at the University of Pittsburgh before starting at the institute. He’s also the founder of Knopp Biosciences, LLC and Iron Horse Diagnostics. Bowser’s expertise lends itself to the company’s scientific breakthroughs in medicine.
The notable leadership at Avant Diagnostics should enable the success of its scientific developments in disease prevention and treatment. Currently, the company’s OvaDx® Pre-Symptomatic Ovarian Cancer Screening Test is at the forefront of Ovarian Cancer detection. The company aims to have this product available for commercialization after FDA approval.
For more information, visit the company’s website at www.avantdiagnostics.com
Let us hear your thoughts: Avant Diagnostics, Inc. Message Board
